Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Open access
Lu, Hezhe, Liu, Shujing, Zhang, Gao, Bin Wu, Zhu, Yueyao, Frederick, Dennie T., Hu, Yi, Zhong, Wenqun, Randell, Sergio, Sadek, Norah, Zhang, Wei, Chen, Gang, Cheng, Chaoran, Zeng, Jingwen, Wu, Lawrence W., Zhang, Jie, Liu, Xiaoming, Xu, Wei, Krepler, Clemens, Sproesser, Katrin, Xiao, Min, Miao, Benchun, Liu, Jianglan, Song, Claire D., Liu, Jephrey Y., Karakousis, Giorgos C., Schuchter, Lynn M., Lu, Yiling, Mills, Gordon, Cong, Yusheng, Chernoff, Jonathan, Guo, Jun, Boland, Genevieve M., Sullivan, Ryan J., Wei, Zhi, Field, Jeffrey, Amaravadi, Ravi K., Flaherty, Keith T., Herlyn, Meenhard, Xu, Xiaowei, Guo, Wei · 2017 · Nature

Abstract

Targeted BRAF inhibition (BRAFi) and combined BRAF and MEK inhibition (BRAFi and MEKi) therapies have markedly improved the clinical outcomes of patients with metastatic melanoma. Unfortunately, the efficacy of these treatments is often countered by the acquisition of drug resistance. Here we investigated the molecular mechanisms that underlie acquired resistance to BRAFi and to the combined therapy. Consistent with previous studies, we show that resistance to BRAFi is mediated by ERK pathway reactivation. Resistance to the combined therapy, however, is mediated by mechanisms independent of reactivation of ERK in many resistant cell lines and clinical samples. p21-activated kinases (PAKs) become activated in cells with acquired drug resistance and have a pivotal role in mediating resistance. Our screening, using a reverse-phase protein array, revealed distinct mechanisms by which PAKs mediate resistance to BRAFi and the combined therapy. In BRAFi-resistant cells, PAKs phosphorylate CRAF and MEK to reactivate ERK. In cells that are resistant to the combined therapy, PAKs regulate JNK and β-catenin phosphorylation and mTOR pathway activation, and inhibit apoptosis, thereby bypassing ERK. Together, our results provide insights into the molecular mechanisms underlying acquired drug resistance to current targeted therapies, and may help to direct novel drug development efforts to overcome acquired drug resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature24040

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 28

  1. Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80–93 (2014) · DOI · Paper page
  2. Boussemart, L. et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 513, 105–109 (2014) · DOI · Paper page
  3. Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867–1876 (2014) · DOI · Paper page
  4. Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877–1888 (2014) · DOI · Paper page
  5. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010) · DOI · Paper page
  6. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683–695 (2010) · DOI · Paper page
  7. Anastas, J. N. et al. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J. Clin. Invest. 124, 2877–2890 (2014) · DOI · Paper page
  8. Tentori, L., Lacal, P. M. & Graziani, G. Challenging resistance mechanisms to therapies for metastatic melanoma. Trends Pharmacol. Sci. 34, 656–666 (2013) · DOI
  9. Moriceau, G. et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27, 240–256 (2015) · DOI · Paper page
  10. Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94–109 (2014) · DOI · Paper page
  11. King, A. J. et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396, 180–183 (1998) · DOI · Paper page
  12. Tran, N. H. & Frost, J. A. Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J. Biol. Chem. 278, 11221–11226 (2003) · DOI
  13. Radu, M., Semenova, G., Kosoff, R. & Chernoff, J. PAK signalling during the development and progression of cancer. Nat. Rev. Cancer 14, 13–25 (2014) · DOI · Paper page
  14. Hugo, W. et al. Non-genomic and immune evolution of melanoma acquiring MAPKi Resistance. Cell 162, 1271–1285 (2015) · DOI · Paper page
  15. Ong, C. C. et al. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J. Natl Cancer Inst. 105, 606–607 (2013) · DOI
  16. Murray, B. W. et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl Acad. Sci. USA 107, 9446–9451 (2010) · DOI · Paper page
  17. Cavigelli, M., Dolfi, F., Claret, F. X. & Karin, M. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J. 14, 5957–5964 (1995) · DOI · Paper page
  18. Bagrodia, S., Dérijard, B., Davis, R. J. & Cerione, R. A. Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J. Biol. Chem. 270, 27995–27998 (1995) · DOI · Paper page
  19. Alavi, A., Hood, J. D., Frausto, R., Stupack, D. G. & Cheresh, D. A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301, 94–96 (2003) · DOI · Paper page
  20. Higuchi, M., Onishi, K., Kikuchi, C. & Gotoh, Y. Scaffolding function of PAK in the PDK1–Akt pathway. Nat. Cell Biol. 10, 1356–1364 (2008) · DOI · Paper page
  21. Zhang, G. et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J. Clin. Invest. 126, 1834–1856 (2016) · DOI · Paper page
  22. Coniglio, S. J., Zavarella, S. & Symons, M. H. Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Mol. Cell. Biol. 28, 4162–4172 (2008) · doi:10.1128/mcb.01532-07
  23. Arias-Romero, L. E., Villamar-Cruz, O., Huang, M., Hoeflich, K. P. & Chernoff, J. Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells. Cancer Res. 73, 3671–3682 (2013) · DOI
  24. You, H. et al. JNK regulates compliance-induced adherens junctions formation in epithelial cells and tissues. J. Cell Sci. 126, 2718–2729 (2013) · DOI
  25. Ji, H., Wang, J., Fang, B., Fang, X. & Lu, Z. α-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of β-catenin transactivation. J. Neurooncol. 103, 445–451 (2011) · DOI
  26. Tibes, R. et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512–2521 (2006) · DOI · Paper page
  27. Krepler, C. et al. Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies. Clin. Cancer Res. 22, 1592–1602 (2016) · DOI
  28. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009) · DOI · Paper page

Cited by

See all 169

Metadata

Authors
Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D. T., Hu, Y., Zhong, W., Randell, S., Sadek, N., Zhang, W., Chen, G., Cheng, C., Zeng, J., Wu, L. W., Zhang, J., Liu, X., Xu, W., Krepler, C., Sproesser, K., Xiao, M., Miao, B., Liu, J., Song, C. D., Liu, J. Y., Karakousis, G. C., Schuchter, L. M., Lu, Y., Mills, G., Cong, Y., Chernoff, J., Guo, J., Boland, G. M., Sullivan, R. J., Wei, Z., Field, J., Amaravadi, R. K., Flaherty, K. T., Herlyn, M., Xu, X., & Guo, W.
Venue
Nature
Published
2017-09-27
Volume
550
Issue
7674
Pages
133-136
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2759091821
Cited by
169
References
5
FWCI
8.54
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. https://app.cochat.ai/papers/10.1038/nature24040
The paper
Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D. T., Hu, Y., Zhong, W., Randell, S., Sadek, N., Zhang, W., Chen, G., Cheng, C., Zeng, J., Wu, L. W., Zhang, J., Liu, X., Xu, W., Krepler, C., . . . Guo, W. (2017). PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. https://doi.org/10.1038/nature24040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.